Capricor Therapeutics Faces Securities Fraud Lawsuit
Rosen Law Firm is initiating a securities fraud lawsuit against Capricor Therapeutics. The suit targets investors who purchased the company's securities between December 17, 2025, and July 26, 2026.
Rosen Law Firm has notified purchasers of securities in Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025, and July 26, 2026, inclusive, of their rights.
The firm stated that investors have the opportunity to lead a class action lawsuit alleging securities fraud against Capricor Therapeutics. Lead plaintiff filings are due by September 28, 2026, in the U.S. District Court for the Southern District of New York.
The lawsuit claims that Capricor Therapeutics made false and misleading statements regarding the company's business and future prospects. Specifically, it alleges that the company provided misleading information concerning the clinical results of its treatment candidate, CAP-1002.
Rosen Law Firm is encouraging investors who have suffered losses in their Capricor Therapeutics securities transactions to contact the firm for further information regarding their rights and potential recovery.